RBC Capital analyst, Randall Stanicky, reiterated his Outperform rating on shares of Kempharm (NASDAQ: KMPH) after the company reported 4Q ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE